Canadian Stock Trader

Tag: TSX

  • Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid

    TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) — Sustainable Innovation & Health Dividend Fund (the “Fund”) (TSX: SIH.UN) announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer bid (“NCIB”). Purchases pursuant to the NCIB will be made in the open market through the facilities of the TSX and Alternative Canadian Trading Systems. This NCIB will commence on September 3, 2026 and will terminate on September 2, 2027. In accordance with the Declaration of Trust by which the Fund is governed, market purchases pursuant to its NCIB may be effected by the Fund.

    Originally published via Source Article.

  • GURU Organic Energy to Report Third Quarter 2026 Results

    MONTREAL, Aug. 28, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, will report its financial results for the third quarter ended July 31, 2026 on Thursday, September 10, 2026, before markets open.

    Originally published via Source Article.

  • Golconda Gold Releases Financial and Operating Results for Q2 2026

    TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) — Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQX: GGGOF) is pleased to announce the release of its financial and operating results for the three and six months ended June 30, 2026.

    Originally published via Source Article.

  • GURU Organic Energy to Report Third Quarter 2026 Results

    MONTREAL, Aug. 28, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company”), Canada’s leading organic energy drink brand1, will report its financial results for the third quarter ended July 31, 2026 on Thursday, September 10, 2026, before markets open.

    Originally published via Source Article.

  • Golconda Gold Releases Financial and Operating Results for Q2 2026

    TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) — Golconda Gold Ltd. (“Golconda Gold” or the “Company”) (TSX-V: GG; OTCQX: GGGOF) is pleased to announce the release of its financial and operating results for the three and six months ended June 30, 2026.

    Originally published via Source Article.

  • Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid

    Sustainable Innovation & Health Dividend Fund Normal Course Issuer Bid

    TORONTO, Aug. 28, 2026 (GLOBE NEWSWIRE) — Sustainable Innovation & Health Dividend Fund (the “Fund”) (TSX: SIH.UN) announced that it has filed a notice with the Toronto Stock Exchange (the “TSX”) and received its approval to make a normal course issuer bid (“NCIB”). Purchases pursuant to the NCIB will be made in the open market through the facilities of the TSX and Alternative Canadian Trading Systems. This NCIB will commence on September 3, 2026 and will terminate on September 2, 2027. In accordance with the Declaration of Trust by which the Fund is governed, market purchases pursuant to its NCIB may be effected by the Fund.

  • CORRECTION – Inventronics Announces 2026 Q2 Financial Results

    CALGARY, Alberta, Aug. 27, 2026 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Inventronics Limited (TSX Venture: IVX), please note that certain language was inadvertently carried forward from the Company’s Q1 2026 press release. The corrected release follows:

    Originally published via Source Article.

  • Thérapeutique Knight annonce le dépôt d'une soumission réglementaire supplémentaire pour MINJUVI® (tafasitamab) au Brésil

    MONTRÉAL, 27 août 2026 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (« Knight ») (TSX : GUD), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui avoir déposé une demande supplémentaire auprès de l’ANVISA, l’agence brésilienne de réglementation de la santé, en vue d’obtenir l’autorisation d’une indication supplémentaire pour MINJUVI® (tafasitamab), en association avec le lénalidomide ajouté au R-CHOP (rituximab, cyclophosphamide, doxorubicine, vincristine et prednisone; Tafa-Len-R-CHOP), à titre de traitement de première intention chez les adultes atteints d’un lymphome diffus à grandes cellules B (DLBCL) ou d’un lymphome à cellules B de haut grade (HGBL) n’ayant reçu aucun traitement antérieur. La demande supplémentaire visant cette nouvelle indication a été sélectionnée pour un examen dans le cadre du Project Orbis.

    Originally published via Source Article.

  • Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil

    MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.

    Originally published via Source Article.

  • EnWave Announces Plan to Drive Profitability and Cash Flow Through Streamlined Operations

    VANCOUVER, British Columbia, Aug. 27, 2026 (GLOBE NEWSWIRE) — EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) today announced details pertaining to an operational efficiency plan (the “Plan”) expected to drive profitability and cash flow as first referenced on August 21, 2026, during its fiscal Q3 conference call.

    Originally published via Source Article.